Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Identified a molecule that increases the risk of cardiac insufficiency

28.04.2009
A team of scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra has identified a key enzyme in the development of cardiac insufficiency. This enzyme is involved in the accumulation of fibrous tissues in the hearts of patients with chronic cardiac diseases and deterioration of heart functions.

The research project, published in the journal Hypertension, is part of a project of the “Red Europea de Excelencia en Hipertensión y Enfermedades Cardiovasculares” [European Network of Excellence in Hypertension and Cardiovascular Diseases], in which research groups from Belgium, the Netherlands, Italy, Great Britain, France, Germany, Finland and Poland are all participating. The project also forms part of the “Red Española de Investigación de las Enfermedades Cardiovasculares” [Spanish Network for Research on Cardiovascular Diseases].

Today, cardiac insufficiency affects more than 1,250,000 Spanish men and women over the age of 45. More than half of these people have a life expectancy of less than five years. The accumulation of fibrosis in the heart has been proven to have a significant influence on the development of cardiac insufficiency among patients with chronic heart disease.

New methods for treating patients with heart disease

The research team from the CIMA analyzed the expression of Llysyl oxidase, an enzyme which regulates the amount of fibrous tissue in cardiac muscle. "By means of molecular and histological methods, we have found that the cardiac muscle in patients with cardiac insufficiency contains an excess of this enzyme as well as collagen fiber (which it produces). These factors are associated with the deterioration of cardiac functions," explained Dr. Begoña López, Lead Researcher of the project.

According to the researchers, this project shows that some drugs prescribed for patients with cardiac insufficiency do not actually inhibit the enzyme lysyl oxidase, nor do they reduce fibrosis or improve heart functions. Other drugs however, which are less commonly used, do have these beneficial qualities. “Our work opens new possibilities for treating patients with heart disease through the inhibition of the enzyme. The development of cardiac insufficiency could thus be impeded,” said Begoña López.

Oihane Lakar | EurekAlert!
Further information:
http://www.elhuyar.com

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>